Red blood cell alloimmunization is influenced by the delay between toll-like receptor agonist injection and transfusion

Haematologica

Volumn 101, Issue 2, 2016, Pages 209-218

  Elayeb, Rahma ^a,b,d   Tamagne, Marie ^a,b,d   Bierling, Philippe ^a,b,c,d   Noizat Pirenne, France ^a,b,c,d   Vingert, Benoît ^a,b,d  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b INSERM U955   (France)

^c FACULTÉ DE MÉDECINE   (France)

^d Laboratory of Excellence GR Ex   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD40 ANTIGEN; CD70 ANTIGEN; CD8ALPHA ANTIGEN; CYTOKINE; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 12; LYSOZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NR16 PROTEIN; OX40 LIGAND; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; ANTIBODY; HEN EGG LYSOZYME; LEUKOCYTE ANTIGEN; PEPTIDE; POLYINOSINIC POLYCYTIDYLIC ACID; TLR3 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 3;

ALLOIMMUNIZATION; ANIMAL CELL; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE TRANSFUSION; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MOUSE; NONHUMAN; RED BLOOD CELL ALLOIMMUNIZATION; SPLEEN CELL; VACCINATION; AGONISTS; ANIMAL; ANTIGEN PRESENTATION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ERYTHROCYTE; GENE EXPRESSION; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGY; METABOLISM; SECRETION (PROCESS); SPLEEN; TIME FACTOR; TRANSGENE; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; ANTIGEN PRESENTATION; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; GENE EXPRESSION; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION; INTERLEUKIN-12; MICE; MICE, TRANSGENIC; MURAMIDASE; PEPTIDES; POLY I-C; SPLEEN; TIME FACTORS; TOLL-LIKE RECEPTOR 3; TRANSGENES;

EID: 84957634012     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.134171     Document Type: Article

References (53)

1. Silvy M, Tournamille C, Babinet J, et al. Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica. 2014;99(7): e115-117.
2. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012; 120(3):528-537.
3. Ansart-Pirenne H, Zeliszewski D, Lee K, Martin-Blanc S, Rouger P, Noizat-Pirenne F. Identification of immunodominant alloreactive T-cell epitopes on the Jka red blood cell protein inducing either Th1 or Th2 cytokine expression. Blood. 2004; 104(10):3409-3410.
4. Hoppe C, Klitz W, Vichinsky E, Styles L. HLA type and risk of alloimmunization in sickle cell disease. Am J Hematol. 2009; 84(7):462-464.
5. Stephen J, Cairns LS, Pickford WJ, Vickers MA, Urbaniak SJ, Barker RN. Identification, immunomodulatory activity, and immunogenicity of the major helper T-cell epitope on the K blood group antigen. Blood. 2012; 119(23):5563-5574.
6. Vingert B, Tamagne M, Desmarets M, et al. Partial dysfunction of Treg activation in sickle cell disease. Am J Hematol. 2014; 89(3):261-266.
7. Zhong H, Bao W, Friedman D, Yazdanbakhsh K. Hemin controls T cell polarization in sickle cell alloimmunization. J Immunol. 2014;193(1):102-110.
8. Bao W, Zhong H, Li X, et al. Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and β-thalassemia major. Am J Hematol. 2011;86(12):1001-1006.
9. Vingert B, Tamagne M, Habibi A, et al. Phenotypic differences of CD4+ T cells in response to red blood cell immunization in transfused sickle cell disease patients. Eur J Immunol. 2015;45(6):1868-1879.
10. Hendrickson JE, Hod EA, Perry JR, et al. Alloimmunization to transfused HOD red blood cells is not increased in mice with sickle cell disease. Transfusion. 2012;52(2): 231-240.
11. Desmarets M, Noizat-Pirenne F. Murine models in blood transfusion: allo-immunization, hemolysis. Transfus Clin Biol. 2011;18 (2):115-123.
12. Yu J, Heck S, Yazdanbakhsh K. Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. Am J Hematol. 2007;82(8):691-696.
13. Hendrickson JE, Desmarets M, Deshpande SS, et al. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion. 2006;46(9):1526-1536.
14. Hendrickson JE, Roback JD, Hillyer CD, Easley KA, Zimring JC. Discrete Toll-like receptor agonists have differential effects on alloimmunization to transfused red blood cells. Transfusion. 2008;48(9):1869-1877.
15. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637-650.
16. Hendrickson JE, Chadwick TE, Roback JD, Hillyer CD, Zimring JC. Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells. Blood. 2007;110(7):2736-2743.
17. Smith NH, Hod EA, Spitalnik SL, Zimring JC, Hendrickson JE. Transfusion in the absence of inflammation induces antigenspecific tolerance to murine RBCs. Blood. 2012;119(6):1566-1569.
18. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1-22.
19. Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev. 2010;234(1):18-31.
20. Coquerelle C, Moser M. DC subsets in positive and negative regulation of immunity. Immunol Rev. 2010;234(1):317-334.
21. Gelman AE, Zhang J, Choi Y, Turka LA. Tolllike receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004;172(10):6065-6073.
22. Longhi MP, Trumpfheller C, Idoyaga J, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med. 2009;206(7):1589-1602.
23. Hendrickson JE, Saakadze N, Cadwell CM, et al. The spleen plays a central role in primary humoral alloimmunization to transfused mHEL red blood cells. Transfusion. 2009;49(8):1678-1684.
24. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol. 2015;168(2):291-300.
25. Dadaglio G, Nelson CA, Deck MB, Petzold SJ, Unanue ER. Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Immunity. 1997;6(6):727-738.
26. de Jong EC, Vieira PL, Kalinski P, et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cellpolarizing signals. J Immunol. 2002; 168(4):1704-1709.
27. Lichtenegger FS, Mueller K, Otte B, et al. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS One. 2012;7(9):e44266.
28. Tsujimoto H, Efron PA, Matsumoto T, et al. Maturation of murine bone marrow-derived dendritic cells with poly(I:C) produces altered TLR-9 expression and response to CpG DNA. Immunol Lett. 2006;107(2):155-162.
29. Verdijk RM, Mutis T, Esendam B, et al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol. 1999;163(1):57-61.
30. Schmitt N, Morita R, Bourdery L, et al. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity. 2009;31(1):158-169.
31. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41(4):529-542.
32. Defrance T, Vanbervliet B, Brière F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med. 1992;175(3):671-682.
33. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23-68.
34. Seghatchian J, Krailadsiri P. Red cell storage lesion assessed by the levels of potassium, haemoglobin and annexin V in supernatants. Transfus Apher Sci. 2002;26(2):139-143.
35. Danesh A, Inglis HC, Jackman RP, et al. Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro. Blood. 2014;123(5):687-696.
36. Sadallah S, Amicarella F, Eken C, Iezzi G, Schifferli JA. Ectosomes released by platelets induce differentiation of CD4+T cells into T regulatory cells. Thromb Haemost. 2014;112(6):1219-1229.
37. Sanchez PJ, McWilliams JA, Haluszczak C, Yagita H, Kedl RM. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J Immunol. 2007; 178(3):1564-1572.
38. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol. 2000;1(5):433-440.
39. Arimoto-Miyamoto K, Kadowaki N, Kitawaki T, Iwata S, Morimoto C, Uchiyama T. Optimal stimulation for CD70 induction on human monocyte-derived dendritic cells and the importance of CD70 in naive CD4(+) T-cell differentiation. Immunology. 2010;130(1):137-149.
40. Kurche JS, Burchill MA, Sanchez PJ, Haluszczak C, Kedl RM. Comparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responses. J Immunol. 2010; 185(4):2106-2115.
41. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4 T cells in immunity to viruses. Nat Rev Immunol. 2012; 12(2):136-148.
42. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science. 2002;297(5589):2060-2063.
43. Munroe ME. Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis. Semin Immunol. 2009;21(5): 283-288.
44. Johnson S, Zhan Y, Sutherland RM, et al. Selected Toll-like receptor ligands and viruses promote helper-independent cytotoxic T cell priming by upregulating CD40L on dendritic cells. Immunity. 2009;30(2):218-227.
45. Garratty G. Autoantibodies induced by blood transfusion. Transfusion. 2004;44(1):5-9.
46. Noizat-Pirenne F, Bachir D, Chadebech P, et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2007;92(12):e132-135.
47. Michel M, Habibi A, Godeau B, et al. Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases. Semin Arthritis Rheum. 2008;38(3):228-240.
48. Toly-Ndour C, Rouquette AM, Obadia S, et al. High titers of autoantibodies in patients with sickle-cell disease. J Rheumatol. 2011;38(2):302-309.
49. Maamar M, Tazi-Mezalek Z, Harmouche H, Mounfaloti W, Adnaoui M, Aouni M. Systemic lupus erythematosus associated with sickle-cell disease: a case report and literature review. J Med Case Rep. 2012; 6(1):366.
50. Kurche JS, Haluszczak C, McWilliams JA, Sanchez PJ, Kedl RM. Type I IFN-dependent T cell activation is mediated by IFNdependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression. J Immunol. 2012;188(2): 585-593.
51. Stüber E, Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med. 1996;183(3):979-989.
52. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine. 2010;28 (Suppl 3):C25-36.
53. Dubensky TW Jr, Reed SG. Adjuvants for cancer vaccines. Semin Immunol. 2010;22 (3):155-161.